Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base.

36 ACLIFORM and AUGMENT showed AB/FF improved E-RS Total score versus placebo (−1.2 units) and both monotherapies (both −0.6 units), 17 although the improvements seen in the 52-week AUGMENT extension study (−0.8, −0.2, and −0.1 units for AB/FF versus placebo, AB, and FF, respectively) did not reach statistical significance. 23 AB/FF improved E-RS Total score by approximately the same amount as the LABA/ICS SAL/FLU (AB/FF −1.0 units and SAL/FLU−0.9 units). 22 AB/FF has also demonstrated improvements in both early-morning and night-time symptom overall scores and their individual domain scores (cough, wheezing, shortne

also in 111,027 other papers